AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10577566 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 362
Study 10577566 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 362
Study 10577566 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 362
Study 7489976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 g daily for 2 months)
Number of subjects: 26
Study 7489976 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (12 g daily for 2 months)
Number of subjects: 26
Study 2278890 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine radionuclide bone scans every 6 months during the first 2 years of follow-up
Number of subjects: 560
Study 2278890 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine radionuclide bone scans
Number of subjects: 560
Study 87094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenutex (0.5% DDT, 2% disulfiram, 22.5% benzyl benzoate)
Number of subjects: 38
Study 87094 — intervention group
Group type: COMPARATOR
Intervention: DDT-free Tenutex emulsion (2% disulfiram, 22.5% benzyl benzoate)
Number of subjects: 38
Study 30904595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 0
Study 30904595 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg PRN
Number of subjects: 0
Study 30022334 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured written and verbal education by community pharmacists
Number of subjects: 64
Study 30022334 — intervention group
Group type: COMPARATOR
Intervention: Verbal advice only (Control)
Number of subjects: 64
Study 26174879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Sangha comorbidity index
Number of subjects: 7808
Study 26174879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Wolfe comorbidity index
Number of subjects: 7808
Study 25127405 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT (15 mg/16 h transdermal patches)
Number of subjects: 1050
Study 25127405 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study 22748590 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 708
Study 22748590 — intervention group
Group type: COMPARATOR
Intervention: ATV/RTV+FTC/TDF
Number of subjects: 708
Study 19890256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 12
Study 19890256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus with full manual review
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus with partial manual review
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring by Somnolyzer24X7 with partial manual review
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Full manual scoring
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring by Morpheus
Number of subjects: 82
Study 18041489 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated scoring by Somnolyzer24X7
Number of subjects: 82
Study 18041489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16050054 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 FA + policosanol 5 mg/day
Number of subjects: 90
Study 16050054 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 FA + policosanol 10 mg/day
Number of subjects: 90
Study 16050054 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 FA + placebo
Number of subjects: 90
Study 14624217 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0
Study 14624217 — intervention group
Group type: EXPERIMENTAL
Intervention: Other coagulation modulators
Number of subjects: 0
Study 14624217 — intervention group
Group type: COMPARATOR
Intervention: Standard management protocols
Number of subjects: 0
Study 11221091 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM plus low-dose Convit vaccine
Number of subjects: 90
Study 11221091 — intervention group
Group type: COMPARATOR
Intervention: Single-dose ROM therapy
Number of subjects: 90
Study 8971431 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg controlled-release (CR) oxycodone tablets
Number of subjects: 24
Study 8971431 — intervention group
Group type: COMPARATOR
Intervention: 20 mg immediate-release (IR) oxycodone oral solution
Number of subjects: 24
Study 1732652 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mL/d of caffeinated coffee
Number of subjects: 100
Study 6147256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloranolol (Tobanum)
Number of subjects: 2066
Study 6147256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2066
Study 6147256 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled questionnaire inquiry (no placebo)
Number of subjects: 2066
Study 29571681 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 26
Study 29571681 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 26
Study 30545427 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based messaging intervention
Number of subjects: 0
Study 30545427 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27107906 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block (CG)
Number of subjects: 85
Study 27107906 — intervention group
Group type: COMPARATOR
Intervention: Single-shot group (SSG)
Number of subjects: 85
Study 23823716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa product rich in fibre (15 g each, 2 servings daily for 4 weeks)
Number of subjects: 44
Study 23823716 — intervention group
Group type: COMPARATOR
Intervention: Milk (control)
Number of subjects: 44
Study 22167566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with 25 mg preladenant
Number of subjects: 24
Study 22167566 — intervention group
Group type: COMPARATOR
Intervention: Fasting with 25 mg preladenant
Number of subjects: 24
Study 22167566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with SCH434748
Number of subjects: 24
Study 22167566 — intervention group
Group type: COMPARATOR
Intervention: Fasting with SCH434748
Number of subjects: 24
Study 20018913 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment using intermittent ATRA
Number of subjects: 576
Study 20018913 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment using continuous 6 mercaptopurine plus methotrexate
Number of subjects: 576
Study 20018913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both maintenance treatments
Number of subjects: 576
Study 20018913 — intervention group
Group type: EXPERIMENTAL
Intervention: Early addition of CT to ATRA
Number of subjects: 576
Study 20018913 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 576
Study 20018913 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related cumulative incidence of deaths in complete response (CR)
Number of subjects: 576
Study 18627001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime nutritional supplementation (710 kcal/day)
Number of subjects: 103
Study 18627001 — intervention group
Group type: COMPARATOR
Intervention: Daytime nutritional supplementation (710 kcal/day)
Number of subjects: 103
Study 18627001 — intervention group
Group type: COMPARATOR
Intervention: Both groups (daytime and nighttime)
Number of subjects: 103
Study 15801944 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg in males with renal impairment
Number of subjects: 20
Study 15801944 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 120 mg in healthy males
Number of subjects: 20
Study 12162932 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (lovastatin, pravastatin, simvastatin)
Number of subjects: 0
Study 12162932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, pravastatin, simvastatin
Number of subjects: 0
Study 12162932 — intervention group
Group type: EXPERIMENTAL
Intervention: Other statins (in long-term trials)
Number of subjects: 0
Study 9602956 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg irbesartan tablet under fasted conditions
Number of subjects: 16
Study 9602956 — intervention group
Group type: COMPARATOR
Intervention: 300-mg irbesartan tablet 5 minutes after a high-fat breakfast
Number of subjects: 16
Study 8043714 — intervention group
Group type: EXPERIMENTAL
Intervention: DP-Gln 20 (gly-gln, gly-tyr)
Number of subjects: 16
Study 8043714 — intervention group
Group type: COMPARATOR
Intervention: Vamin 18EF
Number of subjects: 16
Study 2742010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40
Study 2742010 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40
Study 2742010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31603867 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase acupuncture for 30-40 minutes
Number of subjects: 102
Study 31603867 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture (control group)
Number of subjects: 102
Study 29542371 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketamine
Number of subjects: 5
Study 29542371 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mg midazolam
Number of subjects: 5
Study 26902307 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg single-dose albendazole administration
Number of subjects: 209
Study 26902307 — intervention group
Group type: EXPERIMENTAL
Intervention: 60000 μg vitamin A capsule combined with 400 mg single-dose albendazole
Number of subjects: 209
Study 26902307 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 209
Study 25288348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid injection (40 mg triamcinolone acetonide)
Number of subjects: 62
Study 22316635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (up to 42 mg/day)
Number of subjects: 294
Study 22316635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 22316635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Number of subjects: 294
Study 20110117 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU/kg of botulinum toxin A injected into the detrusor muscle (Group A)
Number of subjects: 60
Study 20110117 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 IU/kg of botulinum toxin A injected into the detrusor muscle and 2 IU/kg through 4 injections in external urethral sphincter (Group B)
Number of subjects: 60
Study 17922221 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded FACT Head and Neck Symptom Index (FHNSI)
Number of subjects: 98
Study 17922221 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone FACT Head and Neck Symptom Index (FHNSI)
Number of subjects: 98
Study 17966578 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains 638 and 1333
Number of subjects: 0
Study 17966578 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains 81, 638, 638T and 1333
Number of subjects: 0
Study 17966578 — intervention group
Group type: EXPERIMENTAL
Intervention: All strains
Number of subjects: 0
Study 14983322 — intervention group
Group type: EXPERIMENTAL
Intervention: tinidazole‐iodoform‐phenocamphor paste
Number of subjects: 80
Study 14983322 — intervention group
Group type: COMPARATOR
Intervention: formocresol
Number of subjects: 80
Study 9862558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 133
Study 9862558 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine therapy
Number of subjects: 133
Study 9862558 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo administration
Number of subjects: 133
Study 9862558 — intervention group
Group type: COMPARATOR
Intervention: Educational-supportive group therapy
Number of subjects: 133
Study 7695309 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg single dose
Number of subjects: 463
Study 7695309 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin 800 mg single dose
Number of subjects: 463
Study 2781664 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of dressings on the first postoperative day
Number of subjects: 200
Study 2781664 — intervention group
Group type: COMPARATOR
Intervention: Removal of dressings on the fifth postoperative day
Number of subjects: 200
Study 827989 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic administration
Number of subjects: 400
Study 827989 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotic administration
Number of subjects: 400
Study 7326269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of feedback in pulse rate (PR) change
Number of subjects: 0
Study 7326269 — intervention group
Group type: COMPARATOR
Intervention: No feedback in pulse rate (PR) change
Number of subjects: 0
Study 31611038 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg once daily for 12 months
Number of subjects: 61
Study 31611038 — intervention group
Group type: COMPARATOR
Intervention: placebo once daily for 12 months
Number of subjects: 61
Study 31611038 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg once daily
Number of subjects: 61
Study 31611038 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 61
Study 31611038 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study 29053120 — intervention group
Group type: EXPERIMENTAL
Intervention: Divaza (2 tablets 3 times a day)
Number of subjects: 126
Study 29053120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 26323041 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5-10 μg/kg/min)
Number of subjects: 120
Study 26323041 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.1-0.3 μg/kg/min)
Number of subjects: 120
Study 24292818 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (IFF; 0.8-1.0 mg iron/100 ml)
Number of subjects: 138
Study 24292818 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 138
Study 21944649 — intervention group
Group type: EXPERIMENTAL
Intervention: Postauricular approach
Number of subjects: 15
Study 21944649 — intervention group
Group type: COMPARATOR
Intervention: Preauricular approach
Number of subjects: 15
Study 19756530 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 42
Study 19756530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17562959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure)
Number of subjects: 258
Study 17562959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-CSA suppressed (n=57)
Number of subjects: 258
Study 17562959 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP-CSA unsuppressed (n=43)
Number of subjects: 258
Study 17562959 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=130)
Number of subjects: 258
Study 15466963 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 56
Study 15466963 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56
Study 15466963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 11673752 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/d
Number of subjects: 16
Study 11673752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axis imaging with echo time of 14 ms and flip angle of 45 degrees at rest
Number of subjects: 2
Study 10211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axis imaging with echo time of 14 ms and flip angle of 45 degrees during stress
Number of subjects: 2
Study 10211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Long axis imaging at end-diastole
Number of subjects: 2
Study 10211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing echo time and flip angle
Number of subjects: 2
Study 10211063 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axis plane imaging
Number of subjects: 2
Study 3289769 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA) - Group A (n = 14) received a background infusion of 4 ml/hr 0.125% bupivacaine, with self-administered 4 ml aliquots as required (up to 16 ml/hr).
Number of subjects: 27
Study 3289769 — intervention group
Group type: COMPARATOR
Intervention: Continuous Infusion Epidural Analgesia (CIEA) - Group B (n = 11) received a continuous infusion of 12 ml/hr with the demand-button deactivated.
Number of subjects: 27
Study 3289769 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA) - Group A (n = 14).
Number of subjects: 27
Study 30954071 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC+RIPostC
Number of subjects: 120
Study 30954071 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 27794035 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign metaphor
Number of subjects: 500
Study 27794035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling metaphor
Number of subjects: 500
Study 27794035 — intervention group
Group type: COMPARATOR
Intervention: Plain language
Number of subjects: 500
Study 27794035 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 500
Study 25593485 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 39
Study 23553790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 621
Study 23553790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 621
Study 23553790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Number of subjects: 621
Study 23553790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 21938889 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Instrumental Music Performance (TIMP)
Number of subjects: 35
Study 21938889 — intervention group
Group type: COMPARATOR
Intervention: Traditional Occupational Therapy (TOT)
Number of subjects: 35
Study 18842610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic probiotics
Number of subjects: 0
Study 17122578 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml Hemospan
Number of subjects: 90
Study 17122578 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml Hemospan
Number of subjects: 90
Study 17122578 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (Control)
Number of subjects: 90
Study 15322325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formula consisting of ACEI, AIIRA, CCB, antiplatelet+/−heparin
Number of subjects: 18
Study 10585174 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NETA; 0.5 mg) alone
Number of subjects: 24
Study 10585174 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NETA; 0.5 mg) in combination with estradiol (E2; 1 mg)
Number of subjects: 24
Study 10585174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 mg NETA with 1 mg E2 administered daily for 28 days
Number of subjects: 24
Study 8901825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril and felodipine treatment for 6 months
Number of subjects: 100
Study 8901825 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug washout after treatment
Number of subjects: 100
Study 2053167 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy
Number of subjects: 0
Study 2053167 — intervention group
Group type: EXPERIMENTAL
Intervention: High EPO group
Number of subjects: 0
Study 6660046 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (n = 9)
Number of subjects: 19
Study 6660046 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol (n = 10)
Number of subjects: 19
Study 31578205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 0
Study 31578205 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 0
Study 31578205 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of non-MPN driver mutations (NDM)
Number of subjects: 0
Study 29743106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-foam sonography (HyFoSy)
Number of subjects: 1163
Study 29743106 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 1163
Study 29743106 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFoSy
Number of subjects: 1163
Study 29743106 — intervention group
Group type: COMPARATOR
Intervention: HSG
Number of subjects: 1163
Study 27310880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornisol
Number of subjects: 32
Study 27310880 — intervention group
Group type: COMPARATOR
Intervention: Optisol‐GS
Number of subjects: 32
Study 24226309 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviewing (MI)
Number of subjects: 86
Study 24226309 — intervention group
Group type: COMPARATOR
Intervention: Healthy activity living guide (information only control)
Number of subjects: 86
Study 22855138 — intervention group
Group type: EXPERIMENTAL
Intervention: TOMOX
Number of subjects: 191
Study 22855138 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 191
Study 20695361 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 20695361 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18235123 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of muramyl tripeptide (MTP) to chemotherapy
Number of subjects: 662
Study 18235123 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without MTP
Number of subjects: 662
Study 18235123 — intervention group
Group type: COMPARATOR
Intervention: Addition of ifosfamide to chemotherapy
Number of subjects: 662
Study 15722905 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc LeukoScan SPECT at 4 h
Number of subjects: 22